| Literature DB >> 26881196 |
Małgorzata Dołowy1, Alina Pyka-Pająk1, Katarzyna Filip2, Joanna Zagrodzka2.
Abstract
Mesterolone is a synthetic androgenic steroid indicating a weak anabolic activity. A new, simple in use, and economical TLC-densitometric method in normal phase system (NP-TLC) has been developed and validated for the identification and quantitative determination of mesterolone in bulk drug and in tablet formulation. NP-TLC analysis was performed on aluminium plates precoated with silica gel 60F254 as the stationary phase using chloroform-acetone (40 : 10, v/v) as mobile phase. Densitometric analysis was carried out at λ = 745 nm after staining with phosphomolybdic acid. These conditions were found to give visible (dark blue) spot and sharp peak, respectively, for mesterolone at R F 0.75 ± 0.02 and enabled satisfactory separation of mesterolone from its related substance (potential impurity). The proposed NP-TLC-densitometric method was validated for specificity, linearity, precision, accuracy, robustness, and sensitivity according to ICH guideline and other validation requirements. The limit of detection (LOD) and limit of quantification (LOQ) were 61.0 ng · spot(-1) and 184.0 ng · spot(-1), respectively. The percent content of mesterolone in marketed tablet formulation was found to be 99.40% of label claim. The developed TLC-densitometric method can be successfully used in quality control of mesterolone in bulk material and also tablet formulation.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26881196 PMCID: PMC4735978 DOI: 10.1155/2015/230104
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Chemical structure of mesterolone (a) and its impurity (b).
Chromatographic characteristic of mesterolone analyzed using different NP-TLC plates and chloroform-acetone (40 : 10, v/v) as mobile phase.
| Mobile phase | Chromatographic plates |
| Visualization mode | ||
|---|---|---|---|---|---|
| Densitometric analysis without the use of visualizing agent | Densitometric analysis after derivatizing with 10% sulphuric acid | Densitometric analysis after derivatizing with 10% phosphomolybdic acid (PMA) | |||
|
|
|
| |||
| Chloroform-acetone 40 : 10 (v/v) | Silica gel 60 | 0.66 ± 0.01 | 200 | 467 | 745 |
| Silica gel 60F254
| 0.75 ± 0.02 | 200 | 467 | 745 | |
| Silica gel 60/Kieselguhr F254
| 0.87 ± 0.01 | 248 | 468 | 745 | |
Figure 2Dendrogram of the similarity analysis: R values of mesterolone separated on chromatographic plates Art. 1.05567, Art. 1.05554, and Art. 1.05553 using chloroform-acetone 40 : 10 (v/v) and visualized by phosphomolybdic acid (PMA).
Figure 3Comparison of TLC densitograms (a) and spectrodensitograms (b) of examined mesterolone standard, mesterolone extracted from tablets, and its impurity.
Results of the resolution of mesterolone and its impurity on TLC plates (Art. 1.05554) developed using mobile phase: chloroform-acetone (40 : 10, v/v).
| Parameter | Mesterolone | Impurity A |
|---|---|---|
|
| 0.75 | 0.66 |
|
| 1.54 | |
|
| 1.05 | |
| Δ | 0.09 | |
Figure 4Densitogram of mesterolone extracted from tablets scanned at λ = 745 nm.
Figure 5Calibration plot (a) and plot of residuals (b) for mesterolone in the linear working range.
Recovery studies.
| Drug | Initial amount of mesterolone [ng·spot−1] | Amount of standard mesterolone added [%] | Amount of standard mesterolone added [ng·spot−1] | Amount recovered | % recovery | Mean |
|---|---|---|---|---|---|---|
| Mesterolone (tablet) | 300.0 | 80 | 240.0 | 239.51 | 99.80 | |
| 300.0 | 80 | 240.0 | 239.25 | 99.69 | 0.11 | |
| 300.0 | 80 | 240.0 | 238.97 | 99.57 | ||
| 300.0 | 100 | 300.0 | 302.76 | 100.92 | ||
| 300.0 | 100 | 300.0 | 298.32 | 99.44 | 0.82 | |
| 300.0 | 100 | 300.0 | 298.65 | 99.55 | ||
| 300.0 | 120 | 360.0 | 357.98 | 99.43 | ||
| 300.0 | 120 | 360.0 | 360.96 | 100.27 | 0.48 | |
| 300.0 | 120 | 360.0 | 358.10 | 99.47 |
RSD, relative standard deviation.
Intraday and interday precision of developed method.
| Drug | Initial amount of mesterolone [ng·spot−1] | Intraday | Interday | ||
|---|---|---|---|---|---|
| Amount of mesterolone found | Mean % RSD ( | Amount of mesterolone found ( | Mean % RSD ( | ||
| Mesterolone (tablet) | 200.0 | 197.34 | 0.69 | 196.34 | 1.25 |
| 200.0 | 200.01 | 192.01 | |||
| 200.0 | 198.15 | 196.15 | |||
| 300.0 | 288.35 | 1.67 | 294.25 | 1.12 | |
| 300.0 | 291.45 | 289.85 | |||
| 300.0 | 297.89 | 287.89 | |||
| 400.0 | 387.86 | 1.12 | 397.16 | 1.79 | |
| 400.0 | 396.54 | 391.44 | |||
| 400.0 | 391.32 | 383.22 | |||
RSD, relative standard deviation.
Robustness of the proposed method (n = 3).
| Parameter | % RSD of peak area |
|---|---|
| Amount of mobile phase volume (varied ±5%) | 0.56 |
| Time of activation of the plates at 100 ± 2°C for 20, 30, and 40 minutes before analysis | 0.62 |
| Development distance (±50 mm) | 0.45 |
| Time from spotting to chromatography (±10 min) | 0.58 |
| Duration of saturation (±5 min) | 1.12 |
RSD, relative standard deviation.
Results from assay of mesterolone in tablets [mg·tablet−1] (n = 6).
| Number | Amount detected |
|---|---|
| 1 | 25.12 |
| 2 | 24.76 |
| 3 | 24.32 |
| 4 | 25.01 |
| 5 | 24.94 |
| 6 | 24.93 |
| Average amount found | 24.85 |
| Label claim | 25.00 |
| Standard deviation (SD) | 0.283 |
| % relative standard deviation (RSD) | 1.14 |
| Percentage of label claim | 99.40 |